Follow us twitter facebook
Edition: Global
Click here to subscribe toour free weekly newsletter click here
Science, R&D

Australia scientists develop ’world first’ melanoma blood test

Australian researchers said Wednesday (July 18, 2018) they have developed a blood test for melanoma in its early stages, calling it a “world first” breakthrough that could save many lives.

The scientists, from Edith Cowan University, said the new test could help doctors detect the skin cancer before it spreads through a person’s body.

Patients who have their melanoma detected in its early stage have a five-year survival rate between 90 and 99 percent,” lead researcher Pauline Zaenker said in a statement. She added that survival rates fell to less than 50 percent if the cancer spread in the body. “This is what makes this blood test so exciting as a potential screening tool because it can pick up melanoma in its very early stages when it is still treatable,” Zaenker said.

Australian researchers said Wednesday they have developed a blood test for melanoma in its early stages, calling it a “world first” breakthrough that could save many lives. Photo : © NatchaS / IStock.com

Australian researchers said Wednesday they have developed a blood test for melanoma in its early stages, calling it a “world first” breakthrough that could save many lives. Photo : © NatchaS / IStock.com

The research, published in the journal Oncotarget on Wednesday, included a trial involving 105 patients with melanoma and 104 healthy people. The procedure detected early stage melanoma in 79 percent of cases, the scientists said.

Melanoma is currently detected using a visual scan by a doctor, with areas of concern cut out surgically and biopsied.

Zaenker said the new process involved identifying autoantibodies a person’s body produces in response to the cancer. “We examined a total of 1627 different types of antibodies to identify a combination of 10 antibodies that best indicated the presence of melanoma in confirmed patients relative to healthy volunteers,” she added.

Cancer Council Australia chief executive Sanchia Aranda said the test would be important for high-risk groups, who have to undergo regular inspections of their spots and moles that can be difficult and time consuming. She cautioned that the test did not pick up other types of less deadly, but more common, skin cancers such as squamous cell and basal cell carcinoma.

People need to be very aware of whether they’ve got sun damage or UV damage on their skin, and be alert to changes in any spots or moles,” she told AFP.

The scientists will conduct another clinical trial lasting three years to validate the findings, and hope to have a test that clinics can use after that.

One in every three cancers diagnosed is a skin cancer, according to the World Health Organization, with Australia having among the highest incidences of melanoma in the world.

AFP/Relaxnews

© 2018 - Premium Beauty News - www.premiumbeautynews.com
latest news
Focus
The 31st edition of Luxe Pack Monaco welcomed 9,280 visitors (vs 9,200 in 2017) of which 53% of international professionals.

Luxe Pack Monaco 2018: Number of visitors remains stable

The 31st edition of Luxe Pack Monaco was held from the 1st the 3rd of October 2018 at the Grimaldi Forum. A very positive outcome, according to the organizers who counted 9,280 visitors (vs 9,200 in 2017) of which 53% of international professionals. All sectors targeted by the trade show were represented: perfumery and cosmetics (...)

read more
job opportunities
Experts’ views
Microbiome: Our new reality, complexity (Part 2)

Marie-Alice Dibon
Microbiome: Our new reality, complexity (Part 2)

For those who, 20 years ago, thought they were living the advent of a world in which nothing would ever be simple again, congrats. You had got it all. And yet, you had probably somewhat underestimated the extent of the phenomenon. Complexification and acceleration make a rather explosive mixture. The emergence of the science of the (...)

read more

Features

We use cookies to give you a better browsing experience. By continuing your visit to this site, you accept the use of cookies. Read more and set cookies
close